{
    "clinical_study": {
        "@rank": "97383", 
        "arm_group": {
            "arm_group_label": "Ranalozine", 
            "arm_group_type": "Experimental", 
            "description": "After enrollment in the study, participants will initiate Ranolazine for 4 weeks.  The participant's usual anti-anginal medication regimen will be continued unchanged throughout study duration.  Patients will receive Ranolazine 500 mg orally twice daily for 1 week, and the dose will be increased to 1,000 mg twice daily for an additional 3 weeks if tolerated."
        }, 
        "brief_summary": {
            "textblock": "This study is being done to determine if Ranolazine treatment improves coronary\n      microcirculation function among patients with coronary microcirculation dysfunction. We are\n      also looking to learn if symptomatic improvement of chest pain  during treatment with\n      Ranalozine is related to improved coronary microcirculation function."
        }, 
        "brief_title": "Impact of Ranolazine on Coronary Microcirculatory Resistance", 
        "condition": [
            "Coronary Microcirculation", 
            "Coronary Artery Disease", 
            "Myocardial Disease", 
            "Ischemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease", 
                "Ischemia", 
                "Cardiomyopathies"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  -  Patients with subjective symptoms of ischemia without flow limiting angiographic\n             CAD (<50% epicardial coronary stenosis) and abnormal IMR (>20 U).\n\n          -  Definition of ischemia (any one):\n\n               -  chest pain with dynamic ischemic ECG changes (t wave inversions or > 1 mm ST\n                  depressions\n\n               -  Exercise treadmill testing induced chest pain with \u22651 mm of downsloping or flat\n                  ST segment depression during exercise or recovery; \u22652 mm of ischemic ST\n                  depression at a low workload (stage 2 or less or \u2264130 beats/min); early onset\n                  (stage 1) or prolonged duration (>5 min) of ST depression; multiple leads (>5)\n                  with ST depression\n\n               -  Nuclear stress perfusion defect > 10%\n\n               -  Stress echocardiogram with stress induced wall motion abnormality\n\n        Exclusion Criteria:\n\n          -  - Age < 18 yrs\n\n          -  Flow Limiting epicardial CAD >50%\n\n          -  Life expectancy < 6 months\n\n          -  Recent (<1 week) myocardial infarction or positive biomarkers\n\n          -  Severe aortic stenosis\n\n          -  Contraindications to IMR testing including inability to utilize antithrombotic\n             therapy and/or intravenous adenosine\n\n          -  Contraindications to Ranolazine therapy:\n\n          -  Patients with known hepatic insufficiency, prolonged QT or renal failure (GFR < 60)\n\n          -  use of drugs that inhibit CYP3A such as diltiazem, verapamil, ketoconazole,\n             macrolides and HIV protease inhibitors\n\n          -  Pregnancy, breastfeeding\n\n          -  Patients taking drugs which prolong QT interval"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01815957", 
            "org_study_id": "12-069 MICRO Study"
        }, 
        "intervention": {
            "arm_group_label": "Ranalozine", 
            "description": ".  After enrollment in the study, participants will initiate Ranolazine for 4 weeks.  The participant's usual anti-anginal medication regimen will be continued unchanged throughout study duration.  Patients will receive Ranolazine 500 mg orally twice daily for 1 week, and the dose will be increased to 1,000 mg twice daily for an additional 3 weeks if tolerated.", 
            "intervention_name": "Rnalozine", 
            "intervention_type": "Drug", 
            "other_name": [
                "Ranexa", 
                "Ranalozine"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Ranolazine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "coronary microcirculation", 
            "coronary artery disease", 
            "myocardial disease", 
            "ischemia"
        ], 
        "lastchanged_date": "March 19, 2013", 
        "location": {
            "contact": {
                "email": "BAhmed@Salud.unm.edu", 
                "last_name": "Bina Ahmed, MD", 
                "phone": "505-272-2273"
            }, 
            "contact_backup": {
                "email": "LSalandre@Salud.unm.edu", 
                "last_name": "Lyra Salandre, BA", 
                "phone": "505-272-9898"
            }, 
            "facility": {
                "address": {
                    "city": "Albuquerque", 
                    "country": "United States", 
                    "state": "New Mexico", 
                    "zip": "87131"
                }, 
                "name": "University of New Mexico Health Science Center"
            }, 
            "investigator": {
                "last_name": "Bina Ahmed, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Impact of Ranalozine on Coronary Microcirculatory Resistance- A Prospective Single Center Study to Evaluate the Effect of Ranalozine in Microcirculatory Resistance (MICRO Study)", 
        "overall_contact": {
            "email": "BAhmed@Salud.unm.edu", 
            "last_name": "Bina Ahmed, MD", 
            "phone": "505-272-2273"
        }, 
        "overall_contact_backup": {
            "email": "LAsalandre@salud.unm.edu", 
            "last_name": "Lyra Salandre, BA", 
            "phone": "505-272-9898"
        }, 
        "overall_official": {
            "affiliation": "Assistant Professor, IM Div Cardiology", 
            "last_name": "Bina Ahmed, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Relative change in IMR before and after Ranolazine therapy.  Mean change between the groups will be analyzed using a paired t test.", 
            "measure": "Relative change in IMR before and after Ranolazine therapy.", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01815957"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of New Mexico", 
            "investigator_full_name": "Bina Ahmed", 
            "investigator_title": "Assistant Professor, Internal Medicine Division of Cardiology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Absolute change in SAQ and DASI scores before and after Ranolazine therapy.  Mean change between the groups will be analyzed using a paired t test.", 
                "measure": "Absolute change in SAQ and DASI scores before and after Ranolazine therapy.", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "Compare relative change in IMR among patients with and without symptomatic improvement in angina burden based on SAQ and DASI scores.", 
                "measure": "Compare relative change in IMR among patients with and without symptomatic improvement in angina burden based on SAQ and DASI scores.", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }
        ], 
        "source": "University of New Mexico", 
        "sponsors": {
            "collaborator": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University of New Mexico", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}